Suggested remit: To appraise the clinical and cost effectiveness of lorlatinib within its marketing authorisation for untreated ALK-positive advanced non-small cell lung cancer.
 
Status In progress
Process STA 2018
ID number 3896

Provisional Schedule

Committee meeting 10 February 2022
Expected publication 27 April 2022

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Consultees

Companies sponsors Pfizer (lorlatinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups ALK Positive UK
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Royal College of Physicians

Commentators

Comparator companies Novartis (ceritinib)
  Pfizer (crizotinib)
  Roche (alectinib)
  Takeda (brigatinib)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
10 June 2021 In progress. Invitation to Participate issued
10 June 2021 Invitation to participate
11 March 2021 - 12 April 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance